Exploring Europe's Undiscovered Gems in May 2026

In recent weeks, the pan-European STOXX Europe 600 Index has experienced modest gains amid easing geopolitical tensions and strong corporate earnings, despite pressures from potential U.S. tariffs on EU goods. As investors navigate these dynamic conditions, identifying promising small-cap stocks that can thrive in such an environment involves looking for companies with robust financial health and a clear growth strategy that aligns with current market trends.

Top 10 Undiscovered Gems With Strong Fundamentals In Europe

Click here to see the full list of 353 stocks from our European Undiscovered Gems With Strong Fundamentals screener.

Underneath we present a selection of stocks filtered out by our screen.

Aerostar (BVB:ARS)

Simply Wall St Value Rating: ★★★★★★

Overview: Aerostar S.A. is involved in the manufacture, integration, upgrade, and maintenance of aviation and ground defense systems for the civil aviation industry both within Romania and internationally, with a market cap of RON1.93 billion.

Operations: Aerostar's revenue streams are derived from its activities in the aviation and ground defense sectors, focusing on manufacturing, integration, upgrades, and maintenance services. The company has a market cap of RON1.93 billion.

With a solid track record, Aerostar shines as a promising player in the Aerospace & Defense sector. The company reported first-quarter sales of RON 195.16 million, up from RON 169.36 million last year, and net income rose to RON 41.14 million from RON 21.06 million. Over the past five years, earnings have grown annually by 14.9%, showcasing consistent performance despite not outpacing the industry's recent growth rate of 35%. Trading at roughly 16% below its estimated fair value and being debt-free further boosts its appeal for potential investors seeking quality earnings and positive free cash flow dynamics.

• Click here and access our complete health analysis report to understand the dynamics of Aerostar.

• Assess Aerostar's past performance with our detailed historical performance reports.

Smartoptics Group (OB:SMOP)

Simply Wall St Value Rating: ★★★★★★

Overview: Smartoptics Group ASA offers optical networking solutions and devices across various global regions, with a market cap of NOK5.53 billion.

Operations: Smartoptics generates revenue primarily from the sale of optical networking solutions and devices. The company's financial performance is characterized by a net profit margin of 12.5%, reflecting its ability to manage costs relative to sales effectively.

Smartoptics Group, a nimble player in the optical networking space, has shown impressive growth with earnings surging 62.6% over the past year, outpacing the industry average of 19.4%. The company is debt-free, marking a significant improvement from five years ago when its debt-to-equity ratio was 42.9%. Recent strategic moves include expanding offerings for Pilot Fiber's network in New York and securing large account wins across various regions. Despite these positives, challenges such as volatile share prices and macroeconomic dependencies persist. With projected revenue growth of 25.9% annually over three years, Smartoptics remains an intriguing prospect in the tech sector's landscape.

• Smartoptics Group's strategic focus on large accounts and innovation drives projected 25.9% annual revenue growth. Click here to explore the full narrative on Smartoptics Group's investment potential.

Kuros Biosciences (SWX:KURN)

Simply Wall St Value Rating: ★★★★★★

Overview: Kuros Biosciences AG focuses on the commercialization and development of biologic technologies for musculoskeletal care across the United States, the European Union, and other international markets, with a market cap of CHF810.93 million.

Operations: Kuros Biosciences generates revenue primarily from its medical devices segment, amounting to $146.06 million. The company's financial performance includes a focus on cost management and profitability metrics, with emphasis on net profit margin trends over time.

Kuros Biosciences, a nimble player in the biotech space, has recently turned profitable with net income of US$2.55 million for 2025, contrasting sharply with a net loss of US$4.84 million the previous year. The company reported revenue growth to US$146.06 million from US$85.16 million, indicating robust performance despite market volatility over the past three months. With no debt on its books and trading at 68.9% below estimated fair value, Kuros seems well-positioned for future expansion as it anticipates sales reaching up to US$330 million by 2028 while aiming for at least 35% sales growth this year.

• Navigate through the intricacies of Kuros Biosciences with our comprehensive health report here.

• Understand Kuros Biosciences' track record by examining our Past report.

Key Takeaways

• Explore the 353 names from our European Undiscovered Gems With Strong Fundamentals screener here.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com